You are here: Industry Insights > Inflammatory

News List

From CDMO Pharmaceutical Crisaborole First Generic Drug, Look at the Domestic PDE-4 Inhibitor R&D Development Layout Xiaobin
May 06, 2024
The NMPA official website showed that Zhejiang CDMO Pharmaceutical had submitted an application for the marketing application of crisaborole ointment as a generic drug and it was accepted by the Center for Drug Evaluation.
Palleon Pharmaceuticals secures $100m in Series B funding pharmaceutical-technology
September 18, 2020
Palleon Pharmaceuticals has raised $100m in a Series B financing round to develop drugs targeting glycan-mediated immune regulation to treat cancer and inflammatory diseases.
Novateur Ventures explores new strategy to reduce hyperinflammatory response caused by COVID-19 expresspharma
August 10, 2020
Its study analyses lipid mediators, known as leukotrienes, as the cause for hyperinflammatory response manifested in severe COVID-19 cases.
ProThera, Takeda Enter Anti-Inflammatory Alliance contractpharma
April 24, 2020
To develop a novel plasma-derived Inter-alpha Inhibitor Proteins therapy for the treatment of acute inflammatory conditions.
Type 2 Diabetes Risk Up With Inflammatory Bowel Disease drugs
August 23, 2019
Patients with inflammatory bowel disease (IBD) have increased risk of type 2 diabetes, according to a study published online in Clinical Gastroenterology and Hepatology.
Horizon bulks up sales force ahead of $750M inflammatory eye drug launch fiercepharma
June 28, 2019
Horizon Therapeutics—until recently known as Horizon Pharma—is headed for an FDA filing for its inflammatory eye drug teprotumumab. To prepare for the potential launch, the company has set out to expand its sales team.
Horizon bulks up sales force ahead of $750M inflammatory eye drug launch fiercepharma
June 28, 2019
Horizon Therapeutics—until recently known as Horizon Pharma—is headed for an FDA filing for its inflammatory eye drug teprotumumab. To prepare for the potential launch, the company has set out to expand its sales team.
Oral Steroids Increase Infection Risk in Inflammatory Disease drugs
June 25, 2019
Oral Steroids Increase Infection Risk in Inflammatory Disease.
IL-18 inhibitor drug holds great potential for inflammatory diseases europeanpharmaceuticalreview
April 26, 2019
An international team of researchers has identified the key role that IL-18 protein plays in Still’s disease, making it a prime candidate for IL-18 inhibitor drug that is proving promising in current trials.
Sanofi signs $1bn drug development deal with Denali Therapeutics pharmaceutical-technology
November 06, 2018
Sanofi has entered a deal valued at more than $1bn with US-based Denali Therapeutics to advance potential drug candidates for the treatment of neurological and systemic inflammatory diseases.